+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Hemapheresis in systemic lupus erythematosus



Hemapheresis in systemic lupus erythematosus



Clinical and Experimental Rheumatology 8(Suppl. 5): 51-55



The place of plasma exchange in treating systemic lupus erythematosus remains to be discussed. Currently available clinical data suggest that PE may be a useful additional therapy only in certain subsets of some severe lupus manifestations such as CNS involvement, crescentic glomerulonephritis, and lupus vasculitis. Using PE could also be of interest in certain manifestations of the anti-phospholipid syndrome. The conflict between the rapid improvement seen in some biological abnormalities (circulating immune complexes, ds-DNA antibodies) and the lack of obvious parallel clinical benefits remains a field of stimulating investigation. Next to plasma exchange associated with conventional corticosteroid or immunosuppressive therapies, other approaches could be of value such as the synchronization of plasma exchange and cyclophosphamide pulses, or the selective removal of assumed pathogenetic antibodies or immune complexes. Insufficient data are presently available to interpret the results of the former. The latter methods could offer the advantage of more precisely establishing the role of selectively removed substances in the pathogenesis of SLE.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 040260663

Download citation: RISBibTeXText

PMID: 2245527


Related references

Progressive systemic sclerosis and localized scleroderma morphea with positive lupus erythematosus cell test and unusual systemic manifestations compatible with systemic lupus erythematosus presentation of 14 cases including 1 set of identical twins 1 with scleroderma and the other with systemic lupus erythematosus review of the literature. Medicine (Baltimore) 50(3): 199-222, 1971

Measures of adult systemic lupus erythematosus: updated version of British Isles Lupus Assessment Group (BILAG 2004), European Consensus Lupus Activity Measurements (ECLAM), Systemic Lupus Activity Measure, Revised (SLAM-R), Systemic Lupus Activity Questionnaire for Population Studies (SLAQ), Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). Arthritis Care & Research 63(Suppl. 11): S37-S46, 2012

White matter lesions and brain atrophy in systemic lupus erythematosus patients: correlation to cognitive dysfunction in a cohort of systemic lupus erythematosus patients using different definition models for neuropsychiatric systemic lupus erythematosus. Lupus 27(7): 1140-1149, 2018

Lupus erythematosus. 2. Systemic Lupus erythematosus: antibody symptomatology, other laboratory evidence, diagnosis, course and prognosis; discoid Lupus erythematosus; drug induced Lupus. Archivio Stomatologico 30(4): 901-935, 1989

Sensitivity of the Systemic Lupus Erythematosus Disease Activity Index, British Isles Lupus Assessment Group Index, and Systemic Lupus Activity Measure in the evaluation of clinical change in childhood-onset systemic lupus erythematosus. Arthritis and Rheumatism 42(7): 1354-1360, 1999

Classification of Systemic Lupus Erythematosus: Systemic Lupus International Collaborating Clinics Versus American College of Rheumatology Criteria. A Comparative Study of 2,055 Patients From a Real-Life, International Systemic Lupus Erythematosus Cohort. Arthritis Care & Research 67(8): 1180-1185, 2015

Correlation between systemic lupus erythematosus and anti-convulsants. Case of systemic lupus erythematosus with aggravated lupus and granulocytopenia caused by diphenyl-hydantoin. Naika. Internal Medicine 26(5): 989-994, 1970

Lupus erythematosus tumidus in systemic lupus erythematosus: novel association and possible role of early treatment in prevention of discoid lupus erythematosus. Lupus 13(1): 64-69, 2004

FRI0540Correlation between the European Consensus Lupus Activity Measurement (ECLAM) and the Modified Systemic Lupus Erythematosus Disease Activity Index 2000 (M-SLEDAI 2K) in Juvenile Systemic Lupus Erythematosus (JSLE). Annals of the Rheumatic Diseases 73(Suppl 2): 582.1-582, 2014

Measures of disease activity and damage in pediatric systemic lupus erythematosus: British Isles Lupus Assessment Group (BILAG), European Consensus Lupus Activity Measurement (ECLAM), Systemic Lupus Activity Measure (SLAM), Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), Physician's Global Assessment of Disease Activity (MD Global), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SLICC/ACR DI; SDI). Arthritis Care & Research 63(Suppl. 11): S112-S117, 2012

Correlation between the Modified Systemic Lupus Erythematosus Disease Activity Index 2000 and the European Consensus Lupus Activity Measurement in juvenile systemic lupus erythematosus. Lupus 25(13): 1479-1484, 2016

The lupus erythematosus syndrome: the relationship of discoid (cutaneous) lupus erythematosus to systemic (disseminated) lupus erythematosus. Annals of Internal Medicine 46(4): 678-684, 1957

Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine 72(2): 113-124, 1993

Neuropsychiatric systemic lupus erythematosus (2nd part). Diagnostic and treatment tools in psychiatric or central nervous system manifestations in systemic lupus erythematosus. La Revue de Medecine Interne 33(9): 503-513, 2012

Translation, cultural adaptation and validation of the Systemic Lupus Erythematosus Activity Questionnaire (SLAQ) in a cohort of Italian systemic lupus erythematosus patients. Lupus 27(10): 1735-1741, 2018